Cargando…

Prognostic value of gender and primary tumor location in metastatic colon cancer

Sex might influence prognosis in patients affected by colorectal cancer. We retrospectively studied a cohort of patients affected by metastatic colon cancer (mCC) stratified by sex and primary tumor location. RAS mutational status was also included in the analysis. Overall, 616 patients met the elig...

Descripción completa

Detalles Bibliográficos
Autores principales: Grassadonia, Antonino, Carletti, Erminia, De Luca, Antonella, Vici, Patrizia, Di Lisa, Francesca Sofia, Filomeno, Lorena, Cicero, Giuseppe, De Lellis, Laura, Veschi, Serena, Florio, Rosalba, Brocco, Davide, Di Marino, Pietro, Alberti, Saverio, Gamucci, Teresa, Borrelli, Paola, Cama, Alessandro, Tinari, Nicola
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10539565/
https://www.ncbi.nlm.nih.gov/pubmed/37781086
http://dx.doi.org/10.7150/jca.85748
Descripción
Sumario:Sex might influence prognosis in patients affected by colorectal cancer. We retrospectively studied a cohort of patients affected by metastatic colon cancer (mCC) stratified by sex and primary tumor location. RAS mutational status was also included in the analysis. Overall, 616 patients met the eligibility criteria, 261 women and 355 men. Neither gender, nor RAS mutational status influenced overall survival (OS) in the entire population. As expected, patients with right-sided colon cancer (RCC) had a significant shorter OS compared to those with left-sided colon cancer (LCC) (21.3 vs 33.1 months, p= 0.002). When the analysis was performed stratifying for gender, RCC retained worse prognosis among men (OS 20.5 vs 33.9 months, p= 0.008), but not among women (p= 0.132). Similarly, the presence of RAS mutations had no prognostic effect in women, but was significantly associate with shorter survival in men (OS 29.5 vs 33.7 months, p= 0.046). In addition, when comparing clinical outcome of women or men according to sidedness and RAS mutational status, RCC was associated with dismal prognosis only in men with RAS mutated tumor (OS 17.2 vs 32.3 months, p= 0.008). Our study highlights the importance of gender in the outcome of patients with mCC.